Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-10-25-Speech-2-271-500"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20111025.25.2-271-500"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Founded in 1995, the European Medicines Agency (EMA) is a decentralised European body whose purpose is to protect and promote human and animal health, by evaluating and supervising medicines for human and veterinary use. The EMA is the agency responsible for the scientific analysis of requests to authorise the bringing onto the market of medicines introduced at EU level. In 2009, the EMA budget was EUR 194 million, with 18.52% financed by the European Union and the remainder obtained through fees paid by pharmaceutical companies for services provided. In the report on the EMA’s accounts for the 2009 period, the Court of Auditors expressed reservations about the legality and regularity of transactions, leading the European Parliament to postpone the decision to discharge the implementation of the budget for the financial year 2009. I agree with the decision to grant the Director of the EMA discharge on the implementation of its budget for the financial year 2009, and I support the closure of the accounts for the financial year 2009, given that the EMA has provided the discharge authority with up-to-date information on the level of application of the Internal Audit Service’s recommendations."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples